BENCHMARK HOLDINGS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.75 GBX | -0.56% |
|
-2.82% | +31.42% |
| May. 24 | Samarkand optimistic as eyes adjusted loss reduction | AN |
| Feb. 15 | Benchmark Holdings swings to quarterly loss, but optimistic | AN |
| Sales 2024 * | 164M 210M | Sales 2025 * | 194M 248M | Capitalization | 331M 423M |
|---|---|---|---|---|---|
| Net income 2024 * | -10M -12.77M | Net income 2025 * | 1M 1.28M | EV / Sales 2024 * | 2.38 x |
| Net Debt 2024 * | 60.5M 77.24M | Net Debt 2025 * | 46.5M 59.37M | EV / Sales 2025 * | 1.95 x |
| P/E ratio 2024 * |
-34.7
x | P/E ratio 2025 * |
39.5
x | Employees | 823 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 71.84% |
More Fundamentals
* Assessed data
More news
Latest transcript on Benchmark Holdings plc
| 1 day | -0.56% | ||
| 1 week | -2.82% | ||
| Current month | -0.56% | ||
| 3 months | -3.87% | ||
| 6 months | +27.13% | ||
| Current year | +31.42% |
1 week
43.00
46.71
1 month
42.0347.74
Current year
33.3048.00
1 year
33.1548.00
3 years
33.0065.90
5 years
24.0068.00
10 years
24.00125.75
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 20-05-31 | |
Septima Maguire
DFI | Director of Finance/CFO | 47 | 19-10-31 |
Morten Rye
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kristian Eikre
BRD | Director/Board Member | 47 | 19-03-13 |
| Director/Board Member | 49 | 23-04-16 | |
| Chairman | 63 | 18-05-07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 44.75 | -0.56% | 17,725 |
| 24-05-24 | 45 | +2.97% | 65,334 |
| 24-05-23 | 43.7 | -7.02% | 310,602 |
| 24-05-22 | 47 | +2.06% | 12,002 |
| 24-05-21 | 46.05 | +0.22% | 106,057 |
Delayed Quote London S.E., May 28, 2024 at 11:35 am EDT
More quotes
Benchmark Holdings plc is a United Kingdom-based aquaculture biotechnology company. The Company is focused on providing specialized mission-critical solutions in three complementary areas: genetics, health, and advanced nutrition. The Company operates through three segments: Genetics, Advanced Nutrition, and Health. The Genetics segment is salmon breeding technology combined with production facilities to provide a range of genetic merit ova. The Advanced Nutrition segment manufactures and provides nutrition and health products to the global aquaculture industry. The Health segment is focused on providing health products to the global aquaculture market. The Company has portfolio of various aquaculture species, such as salmon, shrimp, sea bass and sea bream, and tilapia in all the aquaculture regions around the world.
Sector
Fishing & Farming
Calendar
2024-08-21
- Q3 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.4475
GBP
Average target price
0.543
GBP
Spread / Average Target
+21.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.42% | 423M | |
| +9.30% | 3.26B | |
| 0.00% | 1.1B | |
| +5.56% | 768M | |
| -.--% | 506M | |
| -18.49% | 391M | |
| +24.62% | 374M | |
| -14.59% | 350M | |
| +14.61% | 357M | |
| -13.10% | 372M |
- Stock Market
- Equities
- BMK Stock
